Valuation: Verastem, Inc.

Market Cap 59Cr 51Cr 48Cr 44Cr 83Cr 5.64TCr 84Cr 561.31Cr 220.31Cr 2.83TCr 222.41Cr 217.54Cr 9.34TCr P/E 2026 *
-4.27x
P/E 2027 * -6x
Enterprise Value 63Cr 55Cr 51Cr 47Cr 88Cr 6.04TCr 90Cr 601.02Cr 235.9Cr 3.03TCr 238.14Cr 232.93Cr 10TCr EV / Sales 2026 *
5.64x
EV / Sales 2027 * 2.11x
Free-Float
96.13%
Yield 2026 *
-
Yield 2027 * -
1 day+14.04%
1 week+16.21%
Current month+16.21%
1 month+32.68%
3 months+37.83%
6 months+1.05%
Current year-12.69%
1 week 5.58
Extreme 5.58
7.1
1 month 5.06
Extreme 5.0595
7.1
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
03/08/26 Sell

Chief Executive Officer

-1,302 0.0017%
21/05/26 Free

Director

36,000 0.0410%
21/05/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+14.04%+16.21%0.00%-32.80% 59Cr
+8.49%+20.55%+70.77%+110.32% 6.81TCr
+1.25%+2.44%+34.27%+70.43% 5.52TCr
-1.09%+32.96%+19.67%+494.56% 2.86TCr
+10.83%+18.38%+56.20%+6.03% 2.4TCr
+2.72%+3.41%-16.11%-7.96% 2.35TCr
+6.50%+7.56%+44.65%-21.73% 1.84TCr
+6.20%+11.51%+33.87%+693.38% 1.64TCr
-3.88%+16.98%+199.30%+359.77% 1.58TCr
+3.58%+1.96%+43.35%+163.76% 1.34TCr
Average +4.86%+12.14%+48.60%+183.58% 2.64TCr
Weighted average by Cap. +4.38%+13.10%+50.58%+168.02%

Financials

2026 *2027 *
Net sales 11Cr 9.73Cr 9.08Cr 8.33Cr 16Cr 1.07TCr 16Cr 106.56Cr 42Cr 536.33Cr 42Cr 41Cr 1.77TCr 18Cr 16Cr 15Cr 13Cr 25Cr 1.72TCr 26Cr 171.72Cr 67Cr 864.32Cr 68Cr 67Cr 2.86TCr
Net income -16Cr -14Cr -13Cr -12Cr -23Cr -1.56TCr -23Cr -155.41Cr -61Cr -782.23Cr -62Cr -60Cr -2.59TCr -15Cr -13Cr -12Cr -11Cr -21Cr -1.45TCr -22Cr -144.54Cr -57Cr -727.5Cr -57Cr -56Cr -2.41TCr
Net Debt 4.19Cr 3.62Cr 3.38Cr 3.1Cr 5.84Cr 398.77Cr 5.93Cr 40Cr 16Cr 199.87Cr 16Cr 15Cr 660.77Cr -21Cr -18Cr -17Cr -16Cr -29Cr -1.99TCr -30Cr -198.64Cr -78Cr -999.84Cr -79Cr -77Cr -3.31TCr
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
07/26/07 $6.740 +14.04% 43,19,009
06/26/06 $5.910 +0.68% 21,89,459
05/26/05 $5.870 +1.03% 15,54,979
04/26/04 $5.810 +2.11% 17,91,796
03/26/03 $5.690 -1.90% 12,88,075
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.740USD
Average target price
14.88USD
Spread / Average Target
+120.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock